Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT01680939
Other study ID # OSAS-HHSC2012
Secondary ID
Status Unknown status
Phase Phase 3
First received September 4, 2012
Last updated May 24, 2013
Start date May 2012

Study information

Verified date May 2013
Source Hamilton Health Sciences Corporation
Contact Lauren Kelly, MSc. BMSc. PHD candidate
Phone (519) 661-2111
Email lkelly27@uwo.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Every year thousands of young children with obstructive sleep apnea undergo surgery which requires them to be prescribed pain medication. The current standard in North America is administration of opioids, mainly codeine or morphine; however in many areas of the world including Canada, nonsteroidal anti-inflammatory medications such as ibuprofen are used. Some North American surgeons are uncertain regarding the potential of ibuprofen to increase bleeding following surgery. The results of research studies have been inconclusive overall. Due to recent codeine fatalities in children following adenotonsillectomy, codeine has been removed from the formulary at many Pediatric institutions. Some surgeons have begun to use oral morphine as an alternate to codeine, which necessitates the need to find safe alternative analgesics in this treatment group.

The primary objectives of this study is to assess the safety(1) and efficacy (2) of morphine and ibuprofen in children with sleep apnea.

An interim analysis will be conducted after recruitment of 70 patients, to monitor both safety and efficacy


Recruitment information / eligibility

Status Unknown status
Enrollment 120
Est. completion date
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Year to 10 Years
Eligibility Inclusion Criteria:

- diagnosed with OSAS,

- scheduled for tonsillectomy plus/minus adenoid removal at MUMC,

- between the ages of 1-10years

Exclusion Criteria:

- contraindications to analgesia,

- asthma,

- has had previous adenotonsillectomy, or

- any craniofacial,

- neuromuscular or cardiac conditions

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Morphine
0.2-0.5 mg/kg PO q4h
Ibuprofen
10mg/kg PO q6hrs

Locations

Country Name City State
Canada McMaster University Medical Centre Hamilton Ontario

Sponsors (3)

Lead Sponsor Collaborator
Hamilton Health Sciences Corporation The Hospital for Sick Children, University of Western Ontario, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Safety will be assessed by comparing changes in respiratory parameters (oxygen saturation and the number of apnea events per night) following adenotonsillectomy. 1.5 years
Secondary Effectiveness Analgesic effectiveness between treatment groups will be assessed using the visual analog scale and the objective pain scale 1.5 years
Secondary Risk Factors Age, BMI, OSA severity and genetic factors will be compared between treatment groups. Furthermore, these factors will be isolated to determine any correlation exists with respiratory parameter improvement in all enrolled patients. 1.5 years